Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis

Jimin He1†, Yao Jiang2,3†, Liang Liu4**, Zhihua Zuo2 and Chun Zeng1**

1 Department of Neurosurgery, Suining Central Hospital, Suining, China, 2 Department of Clinical Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China, 3 Department of Clinical Laboratory Medicine, Suining Central Hospital, Suining, China, 4 Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China

Backgrounds and Purpose: Currently, circulating microRNAs (miRNAs) are considered to be non-invasive diagnostic biomarkers in a broad range of tumors. Nevertheless, so far, miRNAs have not been fully applied to the clinic for routine screening in glioma patients. Thus, our goal is to evaluate the diagnostic performance of circulating miRNAs for gliomas via a meta-analysis. The present study is registered on the PROSPERO website, with the number CRD42020195883.

Methods: Literature retrieval was implemented in the PubMed, Embase, and Web of Science databases using the established search strategy. We pooled the sensitivity, specificity, and its 95% confidence intervals (CIs) for the included studies using the Stata 14.0 software. In addition, the heterogeneity between studies was assessed via the \( Q \) statistics and \( I^2 \) values calculated by a Chi-square test. A bivariate random effects model was selected due to significant heterogeneity. Specifically, for exploring the factors influencing the heterogeneity, we implemented subgroup and meta-regression analyses. Ultimately, a Deek’s funnel plot asymmetry test was used to estimate the potential publication bias.

Results: A total of 18 articles covering 24 studies were included, containing 2,170 glioma patients and 1,456 healthy participants. The overall pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were 0.84 (95%CI: 0.79–0.87), 0.84 (95%CI: 0.80–0.88), 5.3 (95%CI: 4.1–6.8), 0.19 (95%CI: 0.15–0.25), 27 (95%CI: 18–41), and 0.91 (95%CI: 0.88–0.93), respectively. Additionally, the findings revealed that serum miRNAs and miRNA panels presented superior diagnostic performance.

Conclusion: Thus, circulating miRNAs have the potential to serve as diagnostic biomarkers for gliomas, but need to be verified via a large pool of prospective studies. Additionally, specific miRNAs still need to be elucidated in the diagnosis of a glioma, especially in the early screening stage. The findings may provide diagnostic and therapeutic strategies for the glioma population.

Keywords: microRNAs, glioma, diagnosis, biomarkers, meta-analysis
INTRODUCTION

Gliomas originate from brain glial cells and are the most frequent type of intracranial primary tumors (1), accounting for 28% of all tumors (2), and 81% of malignant brain tumors (3). Based on a published statistical report of CBTRUS in 2019, the researchers found that the average annual age-adjusted incidence rate (AAAIR) of a glioma was approximately 7.87 per 100,000 from 2012 to 2016 in the United States (1). The astrocytoma and oligodendroglioma are the most commonly seen in the glioma population, on the basis of the World Health Organization (WHO) classification, gliomas are classified into a low-grade glioma (LGG, grades I-II), and a high-grade glioma (HGG, grades III-IV) (4, 5), and the WHO also incorporated molecular biomarkers for the sub-classification of gliomas in 2016 (6). According to previously established knowledge, an LGG had an approximate 43% possibility of 10-year survival (7). By contrast, once the patients suffering from an LGG progress to a HGG, especially glioblastoma (GBM) with grade IV, it has been reported that patients only have a 15-month average survival time (8). Thus, the early identification of gliomas is essential for clinicians.

Although computed tomography (CT) and magnetic resonance imaging (MRI) technologies (9) and comprehensive pathological diagnosis have emerged in the clinical setting, on account of exorbitant expenditure and invasive manipulation, these methods are not appropriate for routine screening in clinical practice. In recent years, multiple circulating biomarkers were employed to detect specific types of tumors earlier in the clinical setting, but these hematological molecules were not established in gliomas (10), where these blood-derived markers can function as minimally invasive biomarkers and support the diagnosis of tumors (11). In fact, clinically, there is also a lack of non-invasive, circulating, and feasible biomarkers for the diagnosis of gliomas (12). Thus, the construction of the circulating diagnostic biomarkers of gliomas is still the fundamental goal of improving its diagnosis and treatment.

At present, microRNAs (miRNAs), a category of small non-coding RNA, have aroused the unprecedented attention of the public. miRNAs, with a length of 19–25 nucleotides (nt) (13), combine with the 3′UTR of messenger RNAs (mRNAs) via complete complementary base-pairing, inhibiting the process of mRNA translation into protein, and also causing the degradation of mRNA via complete complementary base-pairing (14). It is of critical interest for miRNAs to regulate target genes, since they participate in various pathophysiological pathways and processes (13). Besides, miRNA expression alterations are the pathogenesis of most human malignancies, and the dysregulation of miRNAs also leads to tumor progression, in which miRNAs are regarded as oncogenes or tumor suppressors (15, 16). Similarly, some studies have confirmed that miRNAs played an imperative part in the tumorigenesis (17), progression, metastasis (18), and regulation of the cell cycle checkpoint (19), etc. Thus, many researchers proposed that miRNAs were capable of serving as non-invasive diagnostic biomarkers in a broad range of tumors, for instance, colorectal cancer (20, 21), osteosarcoma (22), breast cancer (23, 24), prostate cancer (25), cervical cancer (26), glioblastoma (27), and gliomas (28). Additionally, evidence from clinical research implied that dysregulated miRNAs were related to the development stage of gliomas (29). Most importantly, it has been demonstrated that miRNAs can be secreted into the blood or outside of cells (30), are stable in the blood circulation system, and present in a form of plasma or serum (31), as well as exosomes (32). Therefore, miRNAs may potentially act as diagnostic biomarkers for a glioma. However, some inconsistent conclusions make it challenging to propel the clinical use of miRNAs in the diagnosis of gliomas, which is pertinent to many categories of miRNAs, various analytic methods among those studies (33), as well as internal reference. Zhi et al. (34) revealed that a miRNA panel originating from serum for diagnosis of a glioma had sensitivity, specificity, and area under the curve (AUC) of 93.3%, 94.5%, and 0.9722 (95%CI: 0.9501–0.9942), respectively. Conversely, Xu et al. (35) found that plasma-derived miR-10b yielded only 44.6% sensitivity, 93.6% specificity, and 0.721 AUC (95%CI: 0.619–0.808). Similarly, Xiao et al. (36) also indicated the diagnostic efficacy of plasma miR-182 with a sensitivity of 58.5%, specificity of 85.2%, and AUC of 0.778 (95%CI: 0.679–0.878). Therefore, due to the present limitations in a single study, we conducted this meta-analysis, for the evaluation of the diagnostic value of circulating miRNAs in gliomas. If it is possible, we would like to investigate the diagnostic efficacy of specific miRNAs as glioma biomarkers for guiding clinical diagnosis.

MATERIALS AND METHODS

Search Strategy

The PubMed, Embase, and Web of Science databases were searched by two reviewers (JH and YJ) to collect relevant articles with a deadline of August 18, 2020. Besides, there were no restrictions on the language and publication date. In regard to the literature retrieval strategy, Medical Subject Headings (MeSHs), including “glioma,” “microRNAs,” and “diagnosis” and their entry terms were combined for screening out all the original published studies. The search strategies are described in detail in Supplementary Table 1. Besides, literature listed on related reviews was also manually retrieved for fear that the important articles were omitted. Besides, when the key data were lacking, the two authors would contact the first author. The protocol of this present diagnostic meta-analysis have been registered on PROSPERO (CRD42020195883) and can be found at: https://www.crd.york.ac.uk/prospero/.

Inclusion and Exclusion Criteria

Two reviewers (JH and YJ) independently performed the screening process through reading the titles and abstracts. Any disagreements were settled via discussion. According to the established inclusion and exclusion criteria, eligible articles were included based on the following criteria: (1) the studies were pertinent to miRNAs for the diagnosis of glioma patients; (2) there were complete data in each study used for calculating the value of true positives (TP), false positives (FP), false negatives (FN), and true negatives (TN); and (3) the sample size of each study was required to be at least 30. On the contrary, studies would be excluded when they were
duplicates, reviews, meta-analyses, letters, abstracts, editorial, conference papers, studies without efficient data or irrelevant to the diagnosis of gliomas, as well as those with a sample size < 30.

Data Extraction
The general contents were extracted by two reviewers (JH and CZ), this information included the first author, country of participants, publication data (year), sample source, methods for detecting miRNAs expression, sample size, internal reference for relative quantitative analysis, truncation values, comparison type, and miRNA categories. In addition, the clinical and pathological characteristics of the glioma patients and healthy controls (HC) were also obtained, such as age, the proportion of male patients, WHO grade, tumor size, as well as Karnofsky performance scale (KPS). Most importantly, the information on sensitivity, specificity as well as sample size (including glioma patients and healthy subjects) was required for extraction in each study.

Quality Assessment
Two authors (YJ and ZZ) separately implemented the quality assessment scale of the included 18 articles via employing the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool (37), which contains four domains: patient selection, index test, reference standard, and flow and timing. And every domain can be rated as a high (red), unclear (yellow), or low (green) risk bias. Similarly, applicability concerns in the first three domains were also evaluated through high, unclear, or low risk bias ratings (38).

Statistical Analysis
The appraisal of the heterogeneity among studies was conducted via the Q statistics and $I^2$ of Chi-square test, an $I^2 > 50\%$ and $P < 0.05$ denoted the presence of heterogeneity, where an $I^2 \leq 25\%$, $25\% < I^2 \leq 50\%$, $50\% < I^2 \leq 75\%$, and $I^2 > 75\%$ was representative of modest, moderate, significant, and considerable heterogeneity, respectively (39, 40), if ever, the bivariate random-effects model was fitted for estimating the summary receiver operating characteristic (SROC) curve (41). This model integrates the inexplicable variability into the meta-analysis, takes the negative correlation between sensitivity and specificity into consideration (42), and meets the bivariate normal distribution via the logit transformation of sensitivity and specificity (43). The threshold effect was identified by a Spearman correlation coefficient and $P$-value (44), and a $P < 0.05$ was reflective of the existence of a threshold effect. Additionally, we divided all patients into seven subgroups, including sample source, dysregulated miRNAs, internal reference for relative quantitative analysis, comparison type, miRNA profiling, sample size, and cut-off values setting groups for subgroup and meta-regression analyses. Also, sensitivity analysis was implemented via four plots, which contained a quantile diagram of goodness-of-fit on the basis of residual, a Chi-square probability graph

![Flow Chart](image-url)
# TABLE 1 | The characteristics of the 18 included articles.

| References | Ethnicity | Comparison type | Sample source | Dysregulated miRNAs | Method | Reference | miRNA profiling | Cut-off | Sample size | Sen | Spe | AUC (95%CI) |
|------------|-----------|-----------------|---------------|--------------------|--------|-----------|----------------|---------|-------------|-----|-----|------------|
| Chen et al. (47) | Asian | Glioma vs. HC | Plasma | Up | qRT-PCR | U6 | miR-720 | 3.19 | 122 | 60 | 0.713 | 0.833 | 0.773 (0.706–0.832) |
| Huang et al. (48) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | U6 | miR-376a | 1.95 | 100 | 50 | 0.81 | 0.82 | 0.872 |
| Huang et al. (48) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | U6 | miR-376b | 2.07 | 100 | 50 | 0.82 | 0.78 | 0.89 |
| Huang et al. (48) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | U6 | miR-376c | 2.12 | 100 | 50 | 0.9 | 0.7 | 0.837 |
| Lai et al. (49) | Asian | Glioma vs. HC | Serum | Up | qRT-PCR | miR-16-1 | miR-210 | 2.259 | 126 | 40 | 0.9127 | 0.725 | 0.927 (0.889–0.964) |
| Lan et al. (50) | Asian | Glioma vs. HC | Serum | Up | qRT-PCR | miR-16 | miR-301a | NA | 60 | 43 | 0.862 | 0.932 | 0.937 (0.855–0.987) |
| Qi and Gao (50) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | U6 | miR-33b | 0.069 | 128 | 62 | 0.867 | 0.855 | 0.883 |
| Shao et al. (51) | Asian | Glioma vs. HC | Plasma | Up | qRT-PCR | NA | miR-454-3p | NA | 70 | 70 | 0.9905 | 0.8286 | 0.9063 (0.8487–0.9639) |
| Sun et al. (52) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | cel-miR-39 | miR-128 | 7.139 | 151 | 53 | 0.8675 | 0.8888 | 0.9096 (0.8695–0.9496) |
| Tang et al. (53) | Asian | Glioma vs. HC | Plasma | Down | qRT-PCR | U6 | miR-122 | 1.225 | 74 | 74 | 0.919 | 0.811 | 0.909 |
| Wang et al. (54) | Asian | Glioma vs. HC | Serum | Up | qRT-PCR | U6/RNU48 | miR-214 | NA | 100 | 100 | 0.9 | 0.7 | 0.885 |
| Wang et al. (54) | Asian | Glioma vs. HC | Serum | Up | qRT-PCR | U6/RNU48 | miR-214 | NA | 62 | 100 | 0.7258 | 0.95 | 0.909 |
| Wei et al. (55) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | miR-24 | miR-125b | NA | 33 | 33 | 0.7879 | 0.7576 | 0.839 (0.743–0.935) |
| Xiao et al. (56) | Asian | Glioma vs. HC | Plasma | Up | RT-qPCR | RNU6B | miR-182 | 1.56 | 112 | 54 | 0.855 | 0.852 | 0.778 (0.679–0.878) |
| Xu et al. (57) | Asian | Glioma vs. HC | Plasma | Up | qRT-PCR | U6 | miR-17 | 3.03 | 47 | 45 | 0.893 | 0.553 | 0.787 (0.690–0.865) |
| Xu et al. (58) | Asian | Glioma vs. HC | Plasma | Up | qRT-PCR | U6 | miR-130a | 2.68 | 47 | 45 | 0.702 | 0.652 | 0.720 (0.617–0.807) |
| Xu et al. (58) | Asian | Glioma vs. HC | Plasma | Up | qRT-PCR | U6 | miR-10b | 10.1 | 47 | 45 | 0.446 | 0.936 | 0.721 (0.619–0.808) |
| Xu et al. (58) | Asian | Glioma vs. HC | Plasma | Up | qRT-PCR | U6 | miR-panel | 5.43 | 47 | 45 | 0.723 | 0.851 | 0.872 (0.787–0.932) |
| Yang et al. (59) | Asian | Glioma vs. HC | Serum | Down | RT-qPCR | U6snRNA | miRNA-panel | 5.6085 | 133 | 80 | 0.88 | 0.9787 | 0.972 (0.954–0.990) |
| Yue et al. (60) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | miR-205 | NA | 0.16 | 64 | 45 | 0.863 | 0.922 | 0.935 |
| Zhang et al. (61) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | cel-miR-39 | miR-145-5p | NA | 117 | 50 | 0.846 | 0.78 | 0.895 |
| Zhao et al. (62) | Asian | Glioma vs. HC | Serum | Down | qRT-PCR | RNU44 | miR-451a | 11.977 | 118 | 84 | 0.814 | 0.797 | 0.816 |
| Zhi et al. (63) | Asian | Astrocytoma vs. HC | Serum | Up | qRT-PCR | NA | miR-panel | 5.649 | 90 | 110 | 0.933 | 0.945 | 0.9722 (0.9501–0.9942) |
| Zhu et al. (64) | Asian | Glioma vs. HC | Serum | Up | RT-qPCR | U6 | miR-193b | 1.155 | 122 | 68 | 0.795 | 0.868 | 0.903 |

HC, healthy controls; HGG, high grade glioma; up, upregulated; down, downregulated; NA, not available; Sen, sensitivity; Spe, specificity; AUC, area under the curve; CI, confidence interval.
of Mahalanobis distance squared, used to evaluate the bivariate normality hypothesis, a spike plot for screening out the studies with the most influencing overall diagnostic efficacy via Cook’s distance method, and a scatter diagram for identifying the outliers (45). Additionally, we applied the Deek’s funnel plot asymmetry test to explore whether publication bias existed, with \( P < 0.10 \) indicating the existence of publication bias, which is a key problem of diagnostic meta-analysis (46).

RESULTS

The Characteristics of Studies

We found 684 studies in the PubMed, Embase, and Web of Science databases, then removed 260 duplicates. Through reading titles and abstracts, 401 studies were eliminated. Ultimately, after excluding five studies for incomplete data (\( n = 3 \)) or a small sample size (\( n = 2 \)), 18 eligible articles (28, 34–36, 47–60) containing 24 studies were employed for the meta-analysis. We depicted the flow diagram of the study screening according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (http://www.prisma-statement.org/) (Figure 1). Accordingly, 24 studies contained 2,170 glioma patients and 1,456 healthy participants in the present study. The main characteristics of each study and their diagnostic performance are described in Table 1. Furthermore, the clinical and pathological traits of participants in the included studies are shown in Table 2. The information of HC’s age and the proportion of men in most of the studies was not given, where healthy individuals were described using age and gender-matched healthy volunteers.

Quality Assessment

Figure 2 presents the risk evaluation for bias and clinical concerns. The domains of reference standard and time and flow were not influenced by risk bias. Given that all glioma patients in the included studies were pathologically confirmed, belonging to a case-control study design, most studies were rated as high risk or unclear risk in the first two domains.

### Table 2 | The clinical and pathological characteristics of glioma cases and healthy controls in the included studies.

| References | Age (mean ± SD) | Male (%) | WHO grade | Tumor size | KPS |
|------------|-----------------|----------|-----------|-----------|-----|
|            | Gliomas HC      | Gliomas HC | I II III IV | ≤5 cm ≥5 cm | ≤90 ≥90 |
| Chen et al. (47) | 48.6 ± 6.01 | NA | 63.93 NA | 19 21 35 47 | 76 46 50 72 |
| Huang et al. (48) | NA NA | 70.00 NA | 10 20 30 40 | 68 32 40 60 |
| Lai et al. (49) | 44 (15–73)* | NA | 55.56 NA | 13 35 46 32 | 67 59 53 73 |
| Lan et al. (28) | 46 (30–72)* | NA | 45.00 NA | 10 11 12 27 | NA NA NA NA |
| Qi and Gao     | NA NA | 57.03 NA | 69\(^a\) 59\(^b\) | 58\(^c\) 70\(^d\) 48 80 |
| Shao et al. (51) | 47.2 ±5.6 | 48.4 ± 3.0 | 51.43 50.00 | 8 15 25 22 | NA NA NA NA |
| Sun et al. (52) | NA NA | 55.63 NA | 24 23 43 61 | NA NA NA NA |
| Tang et al. (53) | NA NA | 52.70 NA | 14 17 20 23 | 41 33 NA NA |
| Wang et al. (54) | NA NA | 83.00 NA | 38\(^a\) 62\(^b\) | 66\(^a\) 34\(^d\) 49\(^f\) 51\(^h\) |
| Wei et al. (55) | NA 43.7 (31.3–55.1)* | 60.61 60.61 | 11 11 11\(^b\) | NA NA NA NA |
| Xiao et al. (56) | NA NA | 64.29 NA | 18 23 32 39 | 66 46 42\(^g\) 70\(^i\) |
| Xu et al. (57) | 49.2 (27–74)* | 45.4 (20–68)* | 61.70 55.56 | 16\(^a\) 31\(^b\) | NA NA 25\(^a\) 22\(^b\) |
| Yang et al. (58) | NA 46.8 ±11.5 | 58.65 63.75 | 15\(^d\) 55 45 33 | NA NA NA NA |
| Yue et al. (59) | 45 (30–72)* | 45.2 ± 10.3 | 50.00 53.33 | 7 9 21 27 | NA NA NA NA |
| Zhang et al. (60) | NA NA | 72.65 NA | – – 117 | NA NA 24\(^h\) 93\(^h\) |
| Zhao et al. (61) | NA NA | 60.17 NA | 27 33 33 25 | 53 65 58 60 |
| Zhi et al. (62) | NA NA | 52.22 51.82 | – 28 38 24 | NA NA NA NA |
| Zhu et al. (63) | NA NA | 63.11 NA | 59\(^a\) 63\(^b\) | 68\(^c\) 54\(^d\) 83 39 |

\(^a\) Grades I+II;
\(^b\) Grades III+IV;
\(^c\) Tumor size ≤ 3 cm;
\(^d\) Tumor size ≥ 3 cm;
\(^e\) Tumor volume < 38.2 cm\(^3\);
\(^f\) Tumor volume ≥ 38.2 cm\(^3\);
\(^g\) KPS ≤ 70;
\(^h\) KPS ≥ 70;
\(^i\) KPS ≤ 80;
\(^j\) KPS ≥ 80;
\(^k\) Median (range);
\(^l\) Not use.

HC, healthy controls; KPS, Karnofsky performance scale; WHO, World Health Organization; NA, not available.
Diagnostic Accuracy of miRNAs in Gliomas

A forest plot of 24 studies on the sensitivity and specificity of miRNAs as diagnostic markers of gliomas is illustrated in Figure 3. Besides, the pooled results were listed as follows: sensitivity, 0.84 (95%CI: 0.79–0.87); specificity, 0.84 (95%CI: 0.80–0.88); positive likelihood ratio (PLR), 5.3 (95%CI: 4.1–6.8); negative likelihood ratio (NLR), 0.19 (95%CI: 0.15–0.25); and diagnostic odds ratio (DOR), 27 (95%CI: 18–41). On account of the obvious heterogeneity among studies in sensitivity ($I^2 = 86.06\%$) and specificity ($I^2 = 77.68\%$), the bivariate random-effects model was adopted to estimate the diagnostic performance of miRNAs in gliomas. Subsequently, the SROC curve was generated (Figure 4) and an AUC of 0.91 (95%CI: 0.88–0.93) was determined, which indicated the superior diagnostic value of miRNAs and showed that miRNAs could distinguish glioma patients from the healthy population. Next, a Fagan plot was applied to assess the clinical value of miRNAs in the diagnosis of gliomas. In the first place, the pre-test probability was set to 20%.
Then the positive test presented a post-test probability of 57% with a PLR of 5.3. Besides, the NLR was equal to 0.19, with the negative test reducing the post-test probability to 5% (Figure 5).

Exploring the Sources of Heterogeneity
The existence of heterogeneity attracted our attention. Firstly, we examined whether the threshold effect was at the root of heterogeneity in our study. The results indicated that there was a Spearman correlation coefficient of 0.137 ($P = 0.525$). In essence, the “shoulder arm” shape, representative shape of the threshold effect, was not found in the SROC curve. Thus, the threshold effect was excluded in the present study. Secondly, heterogeneity brought about by other factors was called the non-threshold effect. Besides, the DOR value of each study and the summary DOR value were not distributed along the same straight line, with the results of Cochran-$Q$ and $I^2$ displaying 76.87 and 70.1% ($P = 0.0000$), respectively (Supplementary Figure 1), which denoted that the non-threshold effect may have led to heterogeneity, including the sample source (plasma and serum), comparison type, the dysregulated direction of miRNAs (upregulated and downregulated), internal reference for relative quantitative analysis, miRNA profiling (single miRNA and miRNA panel), sample size ($\geq 100$ and $< 100$), as well as cut-off values setting (given and NA).

Subgroup Analyses, Meta-Regression, and Sensitivity Analyses
Thus, we performed subgroup analyses based on the above mentioned seven subgroups (Table 3) and completed meta-regression analysis (Figure 6). The subgroups of the sample source, dysregulated direction of miRNAs, internal reference, comparison type, miRNA profiling, and cut-off values setting were related to heterogeneity ($P < 0.05$). Conversely, the difference in heterogeneity caused by a sample size subgroup was not statistically significant ($P > 0.05$). Our results indicated that serum miRNAs had superior diagnostic accuracy for glioma patients, with a sensitivity, specificity, PLR, NLR, DOR, and AUC of 0.86 (95%CI: 0.83–0.88), 0.86 (95%CI: 0.81–0.90), 6.0 (95%CI: 4.4–8.3), 0.17 (95%CI: 0.14–0.20), 36 (95%CI: 24–54), and 0.91 (95%CI: 0.88–0.93), respectively. While, the plasma-derived
miRNAs in the diagnosis of gliomas had inferior performance compared to serum miRNAs and the pooled results included sensitivity (0.80, 95%CI: 0.63–0.90), specificity (0.81, 95%CI: 0.72–0.87), PLR (4.1, 95%CI: 2.9–5.9), NLR (0.25, 95%CI: 0.14–0.47), DOR (16, 95%CI: 7–36), and AUC (0.86, 95%CI: 0.83–0.89). Of note, the diagnostic efficacy of the miRNA panel was found to be rather excellent compared to a single miRNA, where the sensitivity, specificity, PLR, NLR, and DOR were 0.87 (95%CI: 0.82–0.91), 0.94 (95%CI: 0.90–0.96), 13 (95%CI: 3.7–45.5), 0.15 (95%CI: 0.06–0.36), and 96 (95%CI: 12–741), respectively. Surprisingly, miRNA expression levels were also pertinent to diagnostic value, the results denoted that upregulated miRNAs presented remarkable diagnostic efficacy (AUC: 0.90, 95%CI: 0.87–0.93). It is also of interest to note that a sample size ≥100 was closely related to better diagnostic value than a sample size of <100 cases, including sensitivity (0.86, 95%CI: 0.81–0.89), specificity (0.86, 95%CI: 0.81–0.89), PLR (5.9, 95%CI: 4.6–7.7), NLR (0.17, 95%CI: 0.13–0.22), DOR (35, 95%CI: 23–53), and AUC (0.92, 95%CI: 0.90–0.94). Additionally, the studies with optimal truncation values yielded pooled results

FIGURE 4 | The summary receiver operating characteristic (SROC) curve of miRNAs as diagnostic biomarkers for gliomas.
FIGURE 5 | Fagan's plot for estimating post-test possibility. The red solid line denotes post-test probability when the index test is positive. While the blue dashed line indicates post-test probability with the negative index test result.
Deek’s funnel plot indicated that publication bias was not found in the meta-analysis. Nevertheless, after removing the four outliers, the pooled results were found to have no significant alterations (Table 2).

**TABLE 2 |** Results of subgroup analysis.

| Covariates | No. studies | Sen (95% CI) | Spe (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC (95% CI) |
|------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Sample source | | | | | | | |
| Plasma | 8 | 0.80 (0.63–0.90) | 0.81 (0.72–0.87) | 4.1 (2.9–5.9) | 0.25 (0.14–0.47) | 16 (7–36) | 0.86 (0.83–0.89) |
| Serum | 16 | 0.86 (0.83–0.88) | 0.86 (0.81–0.90) | 6.0 (4.4–8.3) | 0.17 (0.14–0.20) | 36 (24–54) | 0.91 (0.88–0.93) |
| Dysregulated miRNAs | | | | | | | |
| Up | 13 | 0.82 (0.73–0.89) | 0.84 (0.77–0.90) | 5.3 (3.6–7.8) | 0.21 (0.14–0.33) | 25 (13–47) | 0.90 (0.87–0.93) |
| Down | 11 | 0.85 (0.83–0.87) | 0.84 (0.78–0.88) | 5.3 (3.9–7.2) | 0.17 (0.15–0.21) | 30 (20–46) | 0.88 (0.85–0.90) |
| Internal reference | | | | | | | |
| U6 | 15 | 0.80 (0.74–0.86) | 0.83 (0.77–0.88) | 4.8 (3.5–6.7) | 0.24 (0.18–0.31) | 20 (13–32) | 0.89 (0.86–0.91) |
| Non–U6 | 7 | 0.86 (0.83–0.88) | 0.83 (0.77–0.88) | 5.1 (3.7–7.1) | 0.17 (0.14–0.21) | 30 (19–47) | 0.88 (0.85–0.91) |
| NA | 2 | 0.96 (0.91–0.98) | 0.90 (0.85–0.94) | 9.6 (3.2–29) | 0.05 (0.01–0.17) | 262 (95–724) | NA |
| Comparison type | | | | | | | |
| Gliomas vs. HC | 21 | 0.84 (0.78–0.88) | 0.83 (0.78–0.87) | 4.8 (3.8–6.1) | 0.20 (0.15–0.26) | 24 (16–36) | 0.90 (0.87–0.92) |
| HGG vs. HC | 2 | 0.80 (0.74–0.86) | 0.89 (0.83–0.94) | 7.1 (1.9–26.5) | 0.24 (0.17–0.35) | 30 (12–74) | NA |
| Astrocytomas vs. HC | 1 | 0.933 | 0.945 | – | – | – | 0.97 (0.95–0.99) |
| miRNA profiling | | | | | | | |
| Single miRNA | 21 | 0.83 (0.78–0.87) | 0.82 (0.78–0.86) | 4.7 (3.8–5.8) | 0.20 (0.16–0.26) | 23 (16–32) | 0.89 (0.86–0.92) |
| miRNA panel | 3 | 0.87 (0.82–0.91) | 0.94 (0.90–0.96) | 13 (3.7–45.5) | 0.15 (0.06–0.36) | 96 (12–741) | NA |
| Sample size | | | | | | | |
| ≥100 | 19 | 0.86 (0.81–0.89) | 0.86 (0.81–0.89) | 5.9 (4.6–7.7) | 0.17 (0.13–0.22) | 35 (23–53) | 0.92 (0.90–0.94) |
| <100 | 5 | 0.73 (0.58–0.84) | 0.77 (0.61–0.88) | 3.2 (2.0–5.0) | 0.36 (0.25–0.51) | 9 (6–14) | 0.81 (0.78–0.84) |
| Cut-off values | | | | | | | |
| Given | 18 | 0.82 (0.77–0.87) | 0.84 (0.79–0.88) | 5.2 (3.8–7.0) | 0.21 (0.16–0.28) | 25 (15–40) | 0.90 (0.87–0.92) |
| NA | 6 | 0.87 (0.79–0.93) | 0.85 (0.75–0.91) | 5.6 (3.5–9.2) | 0.15 (0.09–0.25) | 37 (19–73) | 0.92 (0.90–0.94) |

*The number of studies was too small to fit the curve.

Sen, sensitivity; Spe, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; NA, not available; CI, confidence interval.

including sensitivity, specificity, PLR, NLR, DOR, and AUC of 0.82 (95% CI: 0.77–0.87), 0.84 (95% CI: 0.79–0.88), 5.2 (95% CI: 3.8–7.0), 0.21 (95% CI: 0.16–0.28), 25 (95% CI: 15–40), and 0.90 (95% CI: 0.87–0.92), whereas the studies without cut-off values presented preferable diagnostic value, with sensitivity of 0.87 (95% CI: 0.79–0.93), specificity of 0.85 (95% CI: 0.75–0.91), PLR of 5.6 (95% CI: 3.5–9.2), NLR of 0.15 (95% CI: 0.09–0.25), DOR of 37 (95% CI: 19–73), and AUC of 0.92 (95% CI: 0.90–0.94), respectively (Table 2). Furthermore, we also conducted a goodness-of-fit analysis and bivariate normality analysis (Figures 7A,B), showing that our model was robust. The outliers were detected via sensitivity analysis, with a total of four studies deemed to be outliers, including Yang et al., Xu et al. (miR-17 and miR-10b), and Shao et al. (Figures 7C,D). After removing these four outliers, the pooled results were found to have no significant alterations (Table 4).

**Publication Bias**

Subsequently, we implemented a Deek’s funnel plot asymmetry test, as well as a line regression test. Asymmetry (Figure 8A) was observed and the results of the linear regression test were −2.07 (P = 0.05), indicating the existence of publication bias in our meta-analysis. Nevertheless, after removing the four outliers, the Deek’s funnel plot indicated that publication bias was not found (Figure 8B, t = −1.35, P = 0.20).

**DISCUSSION**

In the present study, a total of 18 articles covering 24 studies included 2,170 glioma patients and 1,456 healthy individuals, with the results denoting that the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of miRNAs in the diagnosis of gliomas were 0.84 (95% CI: 0.79–0.87), 0.84 (95% CI: 0.80–0.88), 5.3 (95% CI: 4.1–6.8), 0.19 (95% CI: 0.15–0.25), 27 (95% CI: 18–41), and 0.91 (95% CI: 0.88–0.93), respectively. A pooled PLR of 5.3 referred to the probability of individuals diagnosed with gliomas increasing by 5.3-fold when an miRNA test was positive. Additionally, the value of NLR (0.19) was reflective of only a 19% probability of subjects diagnosed with gliomas if miRNA detection was negative. DOR, an index of discriminatory test performance (61), was employed to assess the discrimination effect of miRNAs in the diagnosis of gliomas, which gave a value of 27 (>1.0), indicating that the circulating miRNAs can effectively differentiate the glioma patients from the healthy population. Qu et al. (62) explored the efficacy of miRNAs as diagnostic markers of gliomas via a meta-analysis and they concluded similar results as follows: sensitivity, 0.87 (95% CI: 0.83–0.91); specificity, 0.87 (95% CI: 0.81–0.91); PLR, 6.6 (95% CI: 4.5–9.6); NLR, 0.15 (95% CI: 0.10–0.21); DOR, 45 (95% CI: 23–90); and AUC, 0.93 (95% CI: 0.91–0.95), indicating the potential diagnostic value of miRNAs for the glioma population. However, subgroup analyses for exploring the sources of...
heterogeneity investigated miRNA profiling, but other factors were neglected. In the present study, through subgroup and meta-regression analyses, the factors influencing heterogeneity contained sample source, dysregulated direction of miRNAs, internal reference, comparison type, miRNAs profiling, as well as cut-off values setting \( (P < 0.05) \). We found that serum miRNAs presented remarkable diagnostic efficacy for gliomas with a sensitivity, specificity, and AUC of 0.86 (95% CI: 0.83–0.88), 0.86 (95% CI: 0.81–0.90), and 0.91 (95% CI: 0.88–0.93), respectively, indicating their promising diagnostic ability for glioma patients. In a previous study, Wang et al. (54) revealed that serum miR-214 gradually escalated with an increase in glioma grade, and had excellent diagnostic efficacy for gliomas (AUC: 0.885, 95% CI: 0.833–0.926). Additionally, Lai et al. (49) showed the outstanding diagnostic value of miR-210 in gliomas with a sensitivity of 0.9127, specificity of 0.725, and AUC of 0.927 (95% CI: 0.889–0.964). Also, Lan et al. (28) proposed that serum exosomal miR-301a could act as a diagnostic biomarker of a glioma and the results were as follows: sensitivity, 0.862; specificity, 0.932; AUC, 0.937 (95% CI: 0.855–0.987). Likewise, Shao et al. (51) constructed a ROC curve for revealing the capability of miR-454-3p in discriminating glioma patients from healthy participants. At the optimal cut-off value of ROC curve, the sensitivity, specificity, and AUC of miR-454-3p were 0.9905, 0.8286, and 0.9063 (95% CI: 0.8487–0.9639), respectively. Sun et al. (52) demonstrated that miR-128 could reliably distinguish glioma patients from healthy individuals, with an AUC of 0.9095 (95% CI: 0.8695–0.9496), and at an optimum cut-off value of 7.139, the sensitivity and specificity were 0.8675 and 0.8868, respectively. Considering that all the studies applied the qRT-PCR method to detect the miRNAs levels, it is necessary to choose a suitable internal reference for normalization, of which U6 is the most common. When U6 was selected as internal reference for relative quantitative analysis, we found that miRNAs showed a similar diagnostic accuracy with other materials known as non-U6 references. Conversely, Xiang et al. (63) found that U6 was not appropriate as an internal reference.

### TABLE 4 | Diagnostic performance of miRNAs in gliomas.

| Analysis | Overall | Outliers excluded |
|----------|---------|-------------------|
| No. of studies | 24 | 20 |
| Sen (95% CI) | 0.84 (0.79–0.87) | 0.83 (0.79–0.87) |
| Spe (95% CI) | 0.84 (0.80–0.88) | 0.83 (0.79–0.87) |
| PLR (95% CI) | 5.3 (4.1–6.8) | 5.0 (4.0–6.3) |
| NLR (95% CI) | 0.19 (0.15–0.25) | 0.20 (0.16–0.25) |
| DOR (95% CI) | 27 (18–41) | 25 (17–36) |
| AUC (95% CI) | 0.91 (0.88–0.93) | 0.90 (0.87–0.92) |

Sen, sensitivity; Spe, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; CI, confidence interval.
reference for miRNA quantitative detection standardization due to its instability. Thus, for the better application of miRNAs in clinical practice as diagnostic biomarkers, it is extremely important to select a unified, suitable, and stable internal reference in the future. In addition, an miRNA panel may be more suitable as a diagnostic biomarker for gliomas, which is the future trend of development on account of miRNAs functioning as a significant sub-class of non-coding RNA. Similarly to our findings, Xu et al. demonstrated that a three plasma-derived miRNA signature had the best diagnostic performance over any other single miRNA, with an AUC of 0.872 (95%CI: 0.78–0.93) (35). In a previous study, Yang et al. (56) conducted serum miRNA profiling analysis, validated seven miRNAs via the quantitative reverse-transcription PCR (RT-qPCR) method, and found that the seven serum miRNA signature had outstanding sensitivity (0.88), specificity (0.9787), and AUC (0.972, 95%CI: 0.954–0.990). Moreover, Zhi et al. (34) established a 9-miRNA panel for evaluating its diagnostic value for astrocytomas, with extraordinary sensitivity (0.933), specificity (0.945), and AUC (0.9722, 95%CI: 0.9501–0.9942). Intriguingly, a higher diagnostic value in the elevated miRNA group was observed, which may be attributed to the fact that upregulated miRNAs were more easily detected than the downregulated group. Additionally, a sample size ≥100 was associated with good diagnostic efficacy, which was demonstrated by Zhi et al. (34), Yang et al. (56), Sun et al. (52), and so on. Thus, a large sample size and large-scale studies will be needed to verify these findings. In addition, for clinical use, a Fagan plot was used for exploring miRNAs as diagnostic markers for estimating the possibility of individuals who would be diagnosed with a glioma, which indicated promising results. When it comes to the detection methods of miRNAs, all studies adopted the qRT-PCR method, which can reverse transcribe an RNA strand into a complementary DNA (cDNA) chain and this cDNA chain will act as a template for the accomplishment of DNA amplification. Therefore, methods for the detection of miRNAs were not taken into account in the subgroup and meta-regression analyses.

However, limitations also need to be highlighted in our meta-analysis. Firstly, due to these studies belonging to retrospective research, a lack of prospective studies increased the bias risk of quality assessment in the patient selection and index test domains. Secondly, there was no consensus about the unified internal reference, leading to inconsistent results in miRNA relative quantitative analysis. Thirdly, the conventional and standard method of miRNA detection was the qRT-PCR method, characterized by complicated, tedious, and time-consuming
manipulation (64), high experimental requirements, and the use of RNA which easily degrades, which limited extensive clinical practice (65). Hence, some novel methods need to be developed for implementing rapid miRNA detection with high sensitivity and selectivity, such as a toehold-mediated strand displacement reaction (SDR) (64), the enzyme-free surface plasmon resonance imaging (SPRi) biosensing method (66), and the ultrasensitive electrochemical method (67), etc. Moreover, the ethnicity of all participants was Asian and they all came from China, with miRNAs showing outstanding diagnostic value for gliomas, but its diagnostic performance may not be suitable for glioma patients worldwide. Additionally, publication bias existed in the present study, but after eliminating the four outliers via sensitivity analysis, the publication bias was found to not be significant, which may be pertinent to the lack of studies with negative results, heterogeneity between-studies, as well as the quality of the included studies. In addition, based on the clinical and pathological characteristics of participants in the included studies, the heterogeneity of tumor types was the inherent limitation of the field. Furthermore, due to a lack of investigation into the diagnostic efficacy of miRNAs in the LGG, the present study lacked the evidence of miRNAs as diagnostic markers for identifying gliomas at an early stage. Ultimately, on account of the absence of similar miRNAs to pool the results, specific miRNAs could not be identified as diagnostic biomarkers for gliomas, which is contrary to our original intention. Therefore, based on the limitations mentioned above, these findings need to be carefully interpreted.

Taken together, the remarkable diagnostic efficacy of circulating miRNAs, especially upregulated serum miRNAs, has gradually emerged for the glioma population. Specifically, an miRNA panel had superior diagnostic value when compared to single miRNA in the diagnosis of gliomas. Nevertheless, a large pool of prospective studies and multi-center research will be required to confirm our findings in the near future. In the next step, we will collect blood samples from LGG patients for an investigation into the potential diagnostic performance of miRNAs and verifying its pivotal functions in early diagnosis.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

JH and YJ designed the project, constructed the search strategy, screened the articles, and drafted the manuscript. JH and CZ extracted the data of the studies included. YJ and ZZ performed the quality assessment and revised the figures. JH, LL, and CZ implemented the data analysis. LL and CZ revised the manuscript and interpreted the results. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported by a Project of Ministry of Education (No.12ZA075). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

ACKNOWLEDGMENTS

We appreciate that Fei Pu, MD and Yongcan Guo, PhD carefully revised our manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.610163/full#supplementary-material
REFERENCES

1. Ostrom QT, Cioffi, G, Gittleman H, Kruchko C, Waite K, Barnholtz-Sloan. J. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. (2019) 1:21-1-100. doi: 10.1093/neuonc/noz150

2. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. (2013) 15:1-56. doi: 10.1093/neuonc/not151

3. Ostrom QT, Bauchet L, Davis GF, Delour I, Fisher JL, Langer CE, et al. The 2017 WHO classification of tumours of the central nervous system. Acta Neuropathol. (2017) 134:107-20. doi: 10.1007/s00401-016-1541-5

4. Van Meir EG, Hladikyan CG, Norden AD, Shuk HK, Wey PF, Olson JL, et al. The epigenetics of glioma in adults: a "state of the science" review. Neuro Oncol. (2014) 16:986-913. doi: 10.1093/neuonc/nou087

5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803-20. doi: 10.1007/s00401-016-1541-5

6. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, St�tzer A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. (2007) 114:97-109. doi: 10.1007/s00401-007-0243-4

7. Smoll NR, Gautchi OP, Schalch B, Schaller K, Weber DC. Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol. (2012) 14:1602-9. doi: 10.1093/neuonc/nou144

8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma multiforme. N Engl J Med. (2005) 352:987-96. doi: 10.1056/NEJMoa043330

9. Mabray MC, Barajas RF, Cha S. Modern brain tumor imaging. Brain Tumor Res Treat. (2015) 3:8-23. doi: 10.14791/brt.2015.3.1.8

10. Regazzo G, Terenato I, Spagnuolo M, Carosi M, Coggetti G, Cicchilliti L, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res. (2015) 34:125. doi: 10.1186/s13046-015-0397-9

11. Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. (2015) 11:556-66. doi: 10.1038/nrneurol.2015.171

12. Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Hunink MG, Stijnen T. Bivariate random effects meta-analysis of ROC curve studies and multivariate meta-analysis of summary measures in diagnostic reviews. Stat Med. (2013) 32:803-20. doi: 10.1002/1:182129

13. Berindan-Neagoe I, Monroig COL, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. J Exp Clin Cancer Res. (2016) 35:124. doi: 10.1186/s13046-016-0393-0

14. Sanz-Rubio D, Martin-Burriel I, Gil A, Cubero P, Forner M, Khalyfa A, et al. Stability of circulating exosomal miRNAs in healthy subjects. Sci Rep. (2018) 8:10306. doi: 10.1038/s41598-018-28748-5

15. Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro-Oncology. (2015) 17:383-91. doi: 10.1093/neuonc/nou169

16. Xuel W, Liang W, Dai Y. A three-miRNA signature as a potential biomarker for the diagnosis of glioma. J Clin Exp Pathol. (2017) 10:8214-3.

17. Yao X, Zhang L, Song Z, Guo C, Zhu J, Li Z, et al. Potential diagnostic and prognostic value of plasma circulating MicroRNA-182 in human glioma. Med Sci Monit. (2016) 22:855-62. doi: 10.12659/MSM.897164

18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. (2011) 155:29-36. doi: 10.7326/0003-4819-155-8-201101080-00009

19. Wade R, Corbett M, Eastwood A. Quality assessment of comparative diagnostic accuracy studies: our experience using a modified version of the QUADAS-2 tool. Res Synth Methods. (2013) 4:280-6. doi: 10.1002/jrsm.1080

20. Moody L, Dvoretskiy S, An R, Mantha S, Pan YX. The efficacy of miR-20a as a diagnostic and prognostic biomarker for colorectal cancer: a systematic review and meta-analysis. Cancers. (2019) 11:1111-124.

21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557-60. doi: 10.1136/bmj.327.7414.557

22. Arends LR, Hamza TH, van Houwelingen JC, Heijenbrok-Kal MH, Hunink MG, Stijnen T. Bivariate random effects meta-analysis of ROC curves. Med Decis Making. (2008) 28:621-38. doi: 10.1177/0727989X08319957

23. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. (2005) 58:962-90. doi: 10.1016/j.cej.2005.02.022

24. Kotz S, Balakrishnan N, Johnson NL. Bivariate and trivariate normal distributions. New York, NY: Wiley (2000). p. 251-348. doi: 10.1002/0471722065

25. Huang C, Wang Q, Ma S, Sun Y, Vadamootoo AS, Jin C. A four serum-miRNA panel serves as a potential diagnostic biomarker of osteosarcoma. Int J Clin Oncol. (2019) 24:976-82. doi: 10.1007/s10147-019-1433-x
44. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. (2006) 6:31. doi: 10.1186/1471-2288-6-31

45. Wu F, Huang Y, Huang X. 99mTc-MIBI scintigraphy for the preoperative assessment of histological response to neoadjuvant chemotherapy in patients with osteosarcoma: a systematic review and a bivariate meta-analysis. Front Oncol. (2020) 10:762. doi: 10.3389/fonc.2020.00762

46. Deeks J, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. (2005) 58:882–93. doi: 10.1016/j.jclinepi.2005.01.016

47. Chen P, Zhang G, Zhou Q, Li Z. Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients. Biosci Rep. (2020) 40:BSR20201449. doi: 10.1042/BSR20201449

48. Huang Q, Wang C, Hou Z, Wang G, Lv J, Wang H, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human glioma. Cancer Biomark. (2017) 19:137–44. doi: 10.3233/CBM-160146

49. Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, et al. Serum microRNA-125b as a potential biomarker for glioma diagnosis. Int J Clin Exp Pathol. (2016) 9:3678–82. doi: 10.3892/ijc.2016.3081

50. Zhao SP, Yue SZ, Yang QH, Cai WM, Jin CL, Gao GJ, et al. Serum microRNA-451a expression and its diagnostic value in glioma. Int J Clin Exp Pathol. (2016) 9:3678–82

51. Shao N, Wang L, Xue L, Wang R, Lan Q. Plasma miR-454-3p as a potential diagnostic marker in glioma. Int J Clin Exp Med. (2015) 8:456–63. doi: 10.2217/bmm-2019-0455

52. Tang Y, Zhao S, Wang J, Li D, Ren Q, Tang Y. Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma. Neurol Sci. (2017) 38:1087–92. doi: 10.1007/s10072-017-2912-y

53. Shao N, Wang L, Xue L, Wang R, Lan Q. Plasma miR-454-3p as a potential diagnostic marker in human glioma. Neurol Sci. (2015) 36:309–13. doi: 10.1007/s10072-014-1938-7

54. Wang J, Che F, Zhang J, Zhang M, Xiao S, Liu Y, et al. Diagnostic and Prognostic potential of serum cell-free microRNA-214 in glioma. World Neurosurg. (2019) 125:e212–7. doi: 10.1016/j.wneu.2019.02.009

55. Wei X, Chen D, Lv T, Li G, Qu S. Serum MicroRNA-125b as a potential biomarker for glioma diagnosis. Mol Neurobiol. (2016) 53:163–70. doi: 10.1007/s12035-014-8893-1

56. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. (2012) 132:116–27. doi: 10.1002/ijc.27657

57. Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. (2016) 124:122–8. doi: 10.3171/2015.1.JNS141577

58. Zhang Y, Ta WW, Sun PE, Meng YF, Zhao CZ. Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. (2019) 12:2536–43.